An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

For the roughly 30 million American adults who have been told their cholesterol is too high but cannot stomach a statin, the treatment menu has been frustratingly short: a modest pill called ezetimibe ...

Genetic PCSK9 inhibition via base editing appeared safe and demonstrated dose-dependent, durable reductions in PCSK9 and LDL cholesterol, researchers reported.At the highest dose, VERVE-102 (Verve ...

Taking steps to lower levels of harmful LDL cholesterol at a much earlier stage than current medical practice indicates could ...

High levels of low-density lipoprotein cholesterol (LDL-C) are a key risk factor for cardiovascular disease, which continues to be one of the leading causes of illness and death globally. LDL-C can ...

A Prescription Drug User Fee Act target date of December 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...

BOSTON -- A PCSK9 inhibitor contributed extra LDL cholesterol lowering as an early add-on to standard high-intensity statins in the acute period of ST-segment elevation MI (STEMI), the small ...

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primatesData reinforce differentiated ...

Use of OTC dietary supplements is increasingly common, sometimes replacing guideline-recommended therapies. Rosuvastatin was associated with larger reductions in LDL-C compared with placebo, fish oil, ...

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...